

**3D PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2017**

Bailey Accountancy & Book Keeping Services

18 New Horizon Bus. Centre
Barrows Road
Harlow
Essex
CM19 5FN

3D Pharma Ltd
Unaudited Financial Statements
For The Year Ended 30 November 2017

Contents

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—5

3D Pharma Ltd
Balance Sheet
As at 30 November 2017

Registered number: 06262236

		2017		2016	
	Notes	£	£	£	£
FIXED ASSETS					
Tangible Assets	5		31,462		-
			<u>31,462</u>		<u>-</u>
CURRENT ASSETS					
Debtors	6	-		9,543	
Cash at bank and in hand		-		5,459	
		<u>-</u>		<u>15,002</u>	
Creditors: Amounts Falling Due Within One Year	7	(29,347)		(11,315)	
		<u>(29,347)</u>		<u>(11,315)</u>	
NET CURRENT ASSETS (LIABILITIES)			(29,347)		3,687
			<u>(29,347)</u>		<u>3,687</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			2,115		3,687
			<u>2,115</u>		<u>3,687</u>
NET ASSETS			2,115		3,687
			<u>2,115</u>		<u>3,687</u>
CAPITAL AND RESERVES					
Called up share capital	8		10		10
Profit and Loss Account			2,105		3,676
			<u>2,105</u>		<u>3,676</u>
SHAREHOLDERS' FUNDS			2,115		3,686
			<u>2,115</u>		<u>3,686</u>

3D Pharma Ltd
Balance Sheet (continued)
As at 30 November 2017

For the year ending 30 November 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities

- The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
- The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Rajbinder Kaur

19th June 2018

The notes on pages 3 to 5 form part of these financial statements.

3D Pharma Ltd
Notes to the Financial Statements
For The Year Ended 30 November 2017

1. Accounting Policies

1.1. Basis of Preparation of Financial Statements

The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

1.2. Turnover

Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.

1.3. Tangible Fixed Assets and Depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Plant & Machinery	20%
Motor Vehicles	25%

1.4. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and asset reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

3. Average Number of Employees

Average number of employees, including directors, during the year was as follows:

3D Pharma Ltd
Notes to the Financial Statements (continued)
For The Year Ended 30 November 2017

5. Tangible Assets

	Plant & Machinery	Motor Vehicles	Total
	£	£	£
Cost			
As at 1 December 2016	1,432	-	1,432
Additions	-	41,950	41,950
As at 30 November 2017	1,432	41,950	43,382
Depreciation			
As at 1 December 2016	1,432	-	1,432
Provided during the period	-	10,488	10,488
As at 30 November 2017	1,432	10,488	11,920
Net Book Value			
As at 30 November 2017	-	31,462	31,462
As at 1 December 2016	-	-	-

6. Debtors

	2017	2016
	£	£
Due within one year		
Director's loan account	-	9,543
	-	9,543

7. Creditors: Amounts Falling Due Within One Year

	2017	2016
	£	£
Trade creditors	-	73
Bank loans and overdrafts	2,195	-
Corporation tax	6,319	8,886
VAT	2,930	2,356
Director's loan account	17,903	-
	29,347	11,315

8. Share Capital

	2017	2016
Allotted, Called up and fully paid	10	10

9. Directors Advances, Credits and Guarantees

Included within Debtors are the following loans to directors:

The above loan is unsecured, interest free and repayable on demand.

3D Pharma Ltd
Notes to the Financial Statements (continued)
For The Year Ended 30 November 2017

Dividends paid to directors

10. Dividends

	2017	2016
	£	£
On equity shares:		
Final dividend paid	25,000	35,000
	<u>25,000</u>	<u>35,000</u>

11. Ultimate Controlling Party

The company's ultimate controlling party is by virtue of his ownership of 100% of the issued share capital in the company.

12. General Information

3D Pharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 06262236. The registered office is 18 New Horizon Bus. Centre, Barrows Road, Harlow, Essex, CM19 5FN.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.